24/7 Pet Web Search

Search results

1. Results From The WOW.Com Content Network

2. Biden administration says Medicare negotiated price discounts ...

   www.aol.com/news/biden-administration-says...

   The list price of Merck's diabetes drug Januvia will be slashed to $113 for a 30-day supply from $527 as of 2023. Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer, will cost $231 for ...

3. Which 10 prescription drug prices are dropping in 2026 after ...

   www.aol.com/10-prescription-drug-prices-dropping...

   Stelara. Stelara by Janssen Biotech, Inc. is used to treat psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The 2026 list price will drop 66% from $13,836 for a 30-day ...

4. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   Apixaban. Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. [ 6][ 7][ 8] It is used an alternative to warfarin to prevent blood clots following hip or knee replacement and in ...

5. Factbox-Top Medicare drugs headed for price cuts - AOL

   www.aol.com/news/factbox-top-medicare-drugs...

   Jardiance. Boehringer Ingelheim and Eli Lilly's Jardiance is used to treat type-2 diabetes, heart failure and chronic kidney disease. It cost Medicare $7 billion for 1.6 million patients in the ...

6. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Medical use. Direct factor Xa inhibitors include rivaroxaban, apixaban and edoxaban, and are types of direct oral anticoagulant (DOAC), which are blood thinning drugs, one of the classes of antithrombotic drugs. [ 4][ 5][ 6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non ...

7. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   The second one was apixaban (Eliquis), approved in Europe in 2011 and in the United States in 2012. The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. Betrixaban (Bevyxxa) was approved in the US in 2017.